COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), today announced that it has successfully completed enrollment in a Phase 2 clinical trial evaluating Prochymal (remestemcel-L) ...
JDRF Partners with Osiris on a Phase II Trial to Evaluate an Immunomodulatory Cell Therapy Product For Type 1 Diabetes New York, NY – October 25, 2007 – The Juvenile Diabetes Research Foundation ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today the expansion of its intellectual property protection around Prochymal® (remestemcel-L). The United States ...
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for ...
What: C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics, Inc. (Nasdaq:OSIR) will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results